All News

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The FDA has granted priority review to the application for the treatment of patients with small cell lung cancer whose disease has progressed after 2 or more prior lines of therapy.

A landmark trial comparing triple therapy fluticasone furoate/umeclidinium/vilaterol (FF/UMEC/VI [Trelegy Ellipta]) versus FF/VI (Relvar; Breo) or FF/UMEC (Anoro) found the former is markedly better in reducing annual rate of on-treatment of moderate/severe exacerbations in patients with chronic obstructive pulmonary disease (COPD).

The Institute for Clinical and Economic Review (ICER) has released a draft evidence report assessing the clinical effectiveness and economic value of calcitonin gene-related peptide (CGRP) inhibitors for the treatment of chronic or episodic migraines.

New analysis from a phase 3 trial reports that oral, once-daily siponimod (BAF312) consistently reduced disability progression in patients with secondary progressive multiple sclerosis.

Top news of the week from The American Journal of Pharmacy Benefits.

Weather can exacerbate asthma, and one specific trigger is thunderstorm activity.

Top news of the week from Specialty Pharmacy Times.

The health insurer recently launched its Emerging Solutions' platform.

Amazon will not pursue medication distribution to hospitals, due to several issues that have crept up, based on current media analysts.

Certified Diabetes Educators (CDEs) can make a tremendous difference in the lives of people who have diabetes.

Pembrolizumab (Keytruda) met its primary endpoint in the pivotal phase 3 KEYNOTE-042 trial.

Top news of the day from across the health care landscape.

Interviewing prospective pharmacy students is a very rewarding experience.

Top news of the day from across the health care landscape.

A new study comparing triple therapy for chronic obstructive pulmonary disease (COPD) against dual therapy resulted in a lower rate of moderate or severe COPD exacerbations and a lower rate of hospitalizations.

Osimertinib surpassed standard of care with a median progression-free survival of 18.9 months in clinical trials.

HDL cholesterol is known as the good kind, but too much or too little could negatively impact the immune system.

An artificial pancreas can improve blood sugar control for people with type 1 diabetes (T1D), according to a new study.

Officials with the FDA have approved fostamatinib disodium hexahydrate (Tavalisse, Rigel) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

Keeping the pounds off is more difficult than shedding them. Here are the most successful ways to do it.

Pharmacists must take care of themselves before they can help others.

The serious condition leaves children with bowed legs, short stature, and bone and dental pain.

Pharmacist experts continue to talk, and offer some great advice.

Children may have to skip school, be admitted to the hospital, and occasionally, children die from asthma attacks. That's a clear call for better intervention on the part of healthcare providers.

You can 'fake it' until you 'make it,' but for the long run, you want to be the real deal.

Emicizumab-kxwh (Hemlibra, Genentech) is the first medication to show superior efficacy compared with prior factor VIII prophylaxis in intra-patient comparisons.

Most of the survey respondents were unaware of oncology drug shortages but would want to be told about any therapy substitutions caused by short supply.

Top news of the day from across the health care landscape.